Cover Story
Free
By Matthew Bin Han Ong
FDA's passive reliance on self-reporting by hospitals and device manufacturers allowed harm caused by power morcellators to go unnoticed for over two decades—likely contributing to injury and deaths of hundreds of women, according to the U.S. Government Accountability Office said.
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
- How the 2024 elections can impact cancer policy
- NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials
- Less Radical podcast: The origins of modern surgery, radical mastectomy, and the first randomized trials in breast cancer
- Evaluation of cancer care in Ukraine shows good access to treatment despite wartime
Work remains to be done to ensure high-quality care